Vaxcyte CEO Pickering sells 24,461 shares

Vaxcyte, Inc. director and CEO Grant Pickering reported a mix of stock option exercise and share sales in Common Stock on June 18, 2026.

Rhea-AI Filing Summary

Vaxcyte, Inc. director and CEO Grant Pickering reported a mix of stock option exercise and share sales in Common Stock on June 18, 2026. He exercised stock options for 225 shares at $1.79 per share and separately reported open-market sales totaling 24,461 shares at prices around $52.50 per share.

Two 1,000-share sales were attributed to children’s trusts that hold shares for his son and daughter, while 22,461 shares were sold from his direct holdings. After these transactions, Pickering holds 496,939 shares directly and 135,215 shares indirectly through trusts. The filing notes the sales were completed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider PICKERING GRANT

Role CHIEF EXECUTIVE OFFICER

Sold 24,461 shs ($1.28M)

Approx. gross sale proceeds $1.28M

Approx. exercise cost $402.75

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	225	$0.00	$0.00
Exercise	Common Stock	225	$1.79	$402.75
Sale	Common Stock	225	$52.51	$12K
Sale	Common Stock	22,236	$52.50	$1.17M
Sale	Common Stock	1,000	$52.50	$53K
Sale	Common Stock	1,000	$52.50	$53K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 474,703 shares (Direct); Common Stock — 135,215 shares (Indirect, By Children's Trust)

Footnotes (4)

1. F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
2. F2. Shares are held directly by a trust for the benefit of the Reporting Person's son.
3. F3. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
4. F4. Option is fully vested and exercisable.

Key Figures

Shares sold: 24,461 shares Sale price: $52.50/share Additional sale price: $52.51/share +4 more

7 metrics

Shares sold 24,461 shares Total Common Stock sales reported on June 18, 2026

Sale price $52.50/share Price for most Common Stock sales on June 18, 2026

Additional sale price $52.51/share Price for a 225-share Common Stock sale

Options exercise price $1.79/share Exercise price for 225-share stock option

Shares from option exercise 225 shares Common Stock acquired via option exercise

Direct holdings after transactions 496,939 shares Common Stock held directly after June 18, 2026

Indirect holdings after transactions 135,215 shares Common Stock held through children’s trusts after transactions

Key Terms

Rule 10b5-1 trading plan, open-market sale, Stock Option (right to buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy) with underlying security title Common Stock"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

indirect ownership financial

"direct_or_indirect: I, ownership_type: indirect, nature_of_ownership: By Children's Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaxcyte (PCVX) CEO Grant Pickering report in this Form 4?

Grant Pickering reported exercising options and selling Vaxcyte Common Stock. He exercised options for 225 shares at $1.79 and reported open-market sales totaling 24,461 shares at prices around $52.50 per share on June 18, 2026.

How many Vaxcyte (PCVX) shares did Grant Pickering sell and at what prices?

The filing shows total reported sales of 24,461 Common Stock shares. Most were sold at $52.50 per share, with one 225-share sale at $52.51 per share, all described as open-market or private sale transactions on June 18, 2026.

Were any of Grant Pickering’s Vaxcyte (PCVX) sales made under a Rule 10b5-1 plan?

Yes. A footnote states that the sale reported in this Form 4 was effected under a Rule 10b5-1 trading plan adopted on March 3, 2026. Such plans pre-schedule trades, indicating the timing was set in advance rather than decided on the transaction date.

How many Vaxcyte (PCVX) shares does Grant Pickering hold after these transactions?

After the reported transactions, Grant Pickering holds 496,939 Vaxcyte Common Stock shares directly. He also has 135,215 shares held indirectly through children’s trusts, reflecting substantial ongoing ownership following the option exercise and the disclosed sales.

How are the children’s trusts involved in Grant Pickering’s Vaxcyte (PCVX) holdings?

Two 1,000-share sales are reported as indirect transactions by children’s trusts. Footnotes explain these trusts hold shares for his son and daughter. After the transactions, 135,215 shares are reported as held indirectly through these trusts, in addition to his direct holdings.

What stock option activity did Grant Pickering report for Vaxcyte (PCVX)?

He reported exercising a stock option for 225 shares of Vaxcyte Common Stock. The option had a conversion or exercise price of $1.79 per share, was fully vested and exercisable, and related derivative holdings for that option are shown as reduced to zero after the exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 08:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PICKERING GRANT

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		M		225	A	$1.79	497,164	D
Common Stock	06/18/2026		S(1)		225	D	$52.51	496,939	D
Common Stock	06/18/2026		S(1)		22,236	D	$52.5	474,703	D
Common Stock	06/18/2026		S(1)		1,000	D	$52.5	135,215	I	By Children's Trust(2)
Common Stock	06/18/2026		S(1)		1,000	D	$52.5	135,215	I	By Children's Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.79	06/18/2026		M			225	(4)	05/17/2027	Common Stock	225	$0	0	D

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

2. Shares are held directly by a trust for the benefit of the Reporting Person's son.

3. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

4. Option is fully vested and exercisable.

Remarks:

	Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)